{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T03:28:19Z","timestamp":1783740499624,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["R03HS028502"],"award-info":[{"award-number":["R03HS028502"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.msard.2024.105539","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T02:20:40Z","timestamp":1710210040000},"page":"105539","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis"],"prefix":"10.1016","volume":"85","author":[{"given":"Jagadeswara Rao","family":"Earla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieni","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Bentley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2310-901X","authenticated-orcid":false,"given":"Rajender R.","family":"Aparasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2024.105539_bib0039","unstructured":"AHRQ. Clinical classifications software refined (CCSR). Accessed January 9, 2023. https:\/\/www.hcup-us.ahrq.gov\/toolssoftware\/ccsr\/ccs_refined.jsp."},{"issue":"1","key":"10.1016\/j.msard.2024.105539_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2307\/2137284","article-title":"Revisiting the behavioral model and access to medical care: does it matter?","volume":"36","author":"Andersen","year":"1995","journal-title":"J. Health Soc. Behav."},{"issue":"28","key":"10.1016\/j.msard.2024.105539_bib0033","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat. Med."},{"issue":"18","key":"10.1016\/j.msard.2024.105539_bib0032","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1212\/WNL.0000000000012777","article-title":"Applying propensity score methods in clinical research in neurology","volume":"97","author":"Austin","year":"2021","journal-title":"Neurology."},{"issue":"6","key":"10.1016\/j.msard.2024.105539_bib0041","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.msard.2015.08.005","article-title":"Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: an observational study using the US Department of Defense administrative claims database","volume":"4","author":"Capkun","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2024.105539_bib0028","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3111\/13696998.2010.523670","article-title":"Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims","volume":"13","author":"Chastek","year":"2010","journal-title":"J. Med. Econ."},{"issue":"10076","key":"10.1016\/j.msard.2024.105539_bib0001","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(16)32388-1","article-title":"Soelberg S\u00f8rensen P. Evolving concepts in the treatment of relapsing multiple sclerosis","volume":"389","author":"Comi","year":"2017","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.msard.2024.105539_bib0023","doi-asserted-by":"crossref","first-page":"e1016","DOI":"10.1212\/WNL.0000000000007043","article-title":"Validation of an algorithm for identifying MS cases in administrative health claims datasets","volume":"92","author":"Culpepper","year":"2019","journal-title":"Neurology."},{"issue":"1","key":"10.1016\/j.msard.2024.105539_bib0011","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/1352458515604383","article-title":"No evidence of disease activity in multiple sclerosis: implications on cognition and brain atrophy","volume":"22","author":"Damasceno","year":"2016","journal-title":"Mult. Scler."},{"issue":"12","key":"10.1016\/j.msard.2024.105539_bib0007","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.sapharm.2020.02.016","article-title":"Use of disease modifying agents in patients with multiple sclerosis: analysis of ten years of national data","volume":"16","author":"Earla","year":"2020","journal-title":"Res. Social. Adm. Pharm."},{"key":"10.1016\/j.msard.2024.105539_bib0009","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.2147\/PPA.S270557","article-title":"Comparative adherence trajectories of oral fingolimod and injectable disease modifying agents in multiple sclerosis","volume":"14","author":"Earla","year":"2020","journal-title":"Patient. Prefer. Adherence"},{"issue":"6","key":"10.1016\/j.msard.2024.105539_bib0027","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/phar.2810","article-title":"Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis","volume":"43","author":"Earla","year":"2023","journal-title":"Pharmacotherapy."},{"issue":"2","key":"10.1016\/j.msard.2024.105539_bib0006","first-page":"74","article-title":"Expenditure, utilization, and cost of specialty drugs for multiple sclerosis in the US medicaid population, 2008-2018","volume":"13","author":"Elsisi","year":"2020","journal-title":"Am. Health Drug Benefits"},{"issue":"5","key":"10.1016\/j.msard.2024.105539_bib0019","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/JNN.0000000000000395","article-title":"Factors affecting the adherence to disease-modifying therapy in patients with multiple sclerosis","volume":"50","author":"Erbay","year":"2018","journal-title":"J. Neurosci. Nurs."},{"issue":"2","key":"10.1016\/j.msard.2024.105539_bib0017","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/03007995.2016.1248380","article-title":"Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis","volume":"33","author":"Fox","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"issue":"4","key":"10.1016\/j.msard.2024.105539_bib0015","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s40801-021-00251-w","article-title":"Retrospective claims analysis of treatment patterns, relapse, utilization, and cost among patients with multiple sclerosis initiating second-line disease-modifying therapy","volume":"8","author":"Freeman","year":"2021","journal-title":"Drugs Real. World Outcomes."},{"issue":"7","key":"10.1016\/j.msard.2024.105539_bib0044","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1007\/s00415-020-09811-6","article-title":"Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method","volume":"267","author":"Guger","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2024.105539_bib0021","series-title":"Truven Health Ananlytics IBM Watson Health","article-title":"The Truven health MarketScan databases for life sciences researchers","author":"Hansen","year":"2017"},{"issue":"12","key":"10.1016\/j.msard.2024.105539_bib0008","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.18553\/jmcp.2016.22.12.1394","article-title":"Adherence to disease-modifying therapies for multiple sclerosis","volume":"22","author":"Higuera","year":"2016","journal-title":"J. Manage Care Spec. Pharm."},{"issue":"11","key":"10.1016\/j.msard.2024.105539_bib0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.34627","article-title":"Comparison of dimethyl fumarate vs fingolimod and rituximab vs natalizumab for treatment of multiple sclerosis","volume":"4","author":"Hou","year":"2021","journal-title":"JAMa Netw. Open."},{"issue":"3","key":"10.1016\/j.msard.2024.105539_bib0048","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3111\/13696998.2012.667027","article-title":"Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US","volume":"15","author":"Ivanova","year":"2012","journal-title":"J. Med. Econ."},{"issue":"3","key":"10.1016\/j.msard.2024.105539_bib0003","doi-asserted-by":"crossref","first-page":"6513","DOI":"10.4081\/ni.2016.6513","article-title":"Injectable disease modifying agents in multiple sclerosis: pattern of medication use and clinical effectiveness","volume":"8","author":"J\u00e4rvinen","year":"2016","journal-title":"Neurol. Int."},{"issue":"11","key":"10.1016\/j.msard.2024.105539_bib0014","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.clinthera.2020.09.014","article-title":"Treatment patterns and relapses among newly treated multiple sclerosis patients from a retrospective claims analysis","volume":"42","author":"Kantor","year":"2020","journal-title":"Clin. Ther."},{"issue":"1","key":"10.1016\/j.msard.2024.105539_bib0040","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s12883-020-01882-2","article-title":"Treatment patterns and comorbid burden of patients newly diagnosed with multiple sclerosis in the United States","volume":"20","author":"Kern","year":"2020","journal-title":"BMC. Neurol."},{"issue":"23","key":"10.1016\/j.msard.2024.105539_bib0049","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1001\/jama.2018.19271","article-title":"Interventions to improve medication adherence: a review","volume":"320","author":"Kini","year":"2018","journal-title":"JAMa"},{"issue":"6","key":"10.1016\/j.msard.2024.105539_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102826","article-title":"Disease modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis","volume":"20","author":"Liu","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.msard.2024.105539_bib0010","article-title":"Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice","volume":"2","author":"Longbrake","year":"2016","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"19","key":"10.1016\/j.msard.2024.105539_bib0034","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1002\/sim.5753","article-title":"A tutorial on propensity score estimation for multiple treatments using generalized boosted models","volume":"32","author":"McCaffrey","year":"2013","journal-title":"Stat. Med."},{"key":"10.1016\/j.msard.2024.105539_bib0029","unstructured":"Milliman Client Report. Multiple sclerosis: new perspectives on the patient journey - 2019 update2019.; 2019. Accessed January 9, 2023. https:\/\/us.milliman.com\/-\/media\/milliman\/importedfiles\/uploadedfiles\/insight\/2019\/ms-patient-journey-2019.ashx."},{"key":"10.1016\/j.msard.2024.105539_bib0024","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1146\/annurev.clinpsy.121208.131413","article-title":"Group-based trajectory modeling in clinical research","volume":"6","author":"Nagin","year":"2010","journal-title":"Annu Rev. Clin. Psychol."},{"issue":"2\u20133","key":"10.1016\/j.msard.2024.105539_bib0025","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000360229","article-title":"Group-based trajectory modeling: an overview","volume":"65","author":"Nagin","year":"2014","journal-title":"Ann. Nutr. Metab."},{"issue":"10","key":"10.1016\/j.msard.2024.105539_bib0012","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1177\/1352458511406309","article-title":"Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design","volume":"17","author":"Nicholas","year":"2011","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2024.105539_bib0020","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12883-020-01830-0","article-title":"Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis","volume":"20","author":"Nicholas","year":"2020","journal-title":"BMC. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2024.105539_bib0005","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1474-4422(19)30151-6","article-title":"Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis","volume":"18","author":"Ontaneda","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2024.105539_bib0016","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.msard.2018.09.038","article-title":"Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US","volume":"27","author":"Ontaneda","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"17","key":"10.1016\/j.msard.2024.105539_bib0002","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105539_bib0035","unstructured":"RAND Corporation. TWANG: SAS macros tutorial. Accessed January 17, 2023. https:\/\/www.rand.org\/statistics\/twang\/sas-tutorial.html."},{"key":"10.1016\/j.msard.2024.105539_bib0036","unstructured":"RAND Corporation. Tutorial: the MNPS function in the SAS TWANG macros. Accessed January 14, 2023. https:\/\/www.rand.org\/statistics\/twang\/mnps-sas-tutorial.html."},{"issue":"1","key":"10.1016\/j.msard.2024.105539_bib0043","doi-asserted-by":"crossref","first-page":"36","DOI":"10.7224\/1537-2073.2011-038","article-title":"Facilitating medication adherence in patients with multiple sclerosis","volume":"15","author":"Remington","year":"2013","journal-title":"Int. J. MS. Care"},{"issue":"1","key":"10.1016\/j.msard.2024.105539_bib0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"issue":"398","key":"10.1016\/j.msard.2024.105539_bib0031","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/01621459.1987.10478441","article-title":"Model-based direct adjustment","volume":"82","author":"Rosenbaum","year":"1987","journal-title":"J. Am. Stat. Assoc."},{"issue":"3\/4","key":"10.1016\/j.msard.2024.105539_bib0037","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1023\/A:1020363010465","article-title":"Using propensity scores to help design observational studies: application to the tobacco litigation","volume":"2","author":"Rubin","year":"2001","journal-title":"Health Serv. Outcomes. Res. Methodol."},{"issue":"4","key":"10.1016\/j.msard.2024.105539_bib0004","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/practneurol-2015-001139","article-title":"Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis","volume":"15","author":"Scolding","year":"2015","journal-title":"Pract. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2024.105539_bib0047","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12325-010-0093-7","article-title":"Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis","volume":"28","author":"Tan","year":"2011","journal-title":"Adv. Ther."},{"issue":"2","key":"10.1016\/j.msard.2024.105539_bib0046","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrneurol.2016.188","article-title":"Treatment decisions in multiple sclerosis - insights from real-world observational studies","volume":"13","author":"Trojano","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2024.105539_bib0026","first-page":"202","article-title":"Group-based trajectory models to identify sociodemographic and clinical predictors of adherence patterns to statin therapy among older adults","volume":"12","author":"Vadhariya","year":"2019","journal-title":"Am. Health Drug Benefits"},{"issue":"7624","key":"10.1016\/j.msard.2024.105539_bib0022","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"issue":"1\u20132","key":"10.1016\/j.msard.2024.105539_bib0042","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jns.2009.07.017","article-title":"Statistical methods for the analysis of relapse data in MS clinical trials","volume":"285","author":"Wang","year":"2009","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.msard.2024.105539_bib0018","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/03007995.2017.1374937","article-title":"Adherence, persistence, and discontinuation among Hispanic and African American patients with multiple sclerosis treated with fingolimod or glatiramer acetate","volume":"34","author":"Williams","year":"2018","journal-title":"Curr. Med. Res. Opin."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824001184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824001184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T11:40:49Z","timestamp":1738064449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824001184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":49,"alternative-id":["S2211034824001184"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105539","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105539","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105539"}}